GNTA
Genenta ScienceGNTA
GNTA
About: Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
Employees: 14
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
37% more capital invested
Capital invested by funds: $757K [Q2] → $1.04M (+$278K) [Q3]
0% more funds holding
Funds holding: 4 [Q2] → 4 (+0) [Q3]
0% more ownership
Funds ownership: 1.36% [Q2] → 1.36% (+0%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for GNTA.
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta's cell therapy product, ensuring compliance with cGMP standards.
Neutral
PRNewsWire
6 days ago
ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE
Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector 1 SAN FRANCISCO , Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025.
Neutral
GlobeNewsWire
2 months ago
Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Genenta's CEO to present at the U.S. Senate, Washington D.C.at the meeting “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatl
Neutral
GlobeNewsWire
3 months ago
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), marking a significant expansion of the potential applications for Genenta's flagship product, Temferon™. This approval by AIFA is in line with the standards that are harmonized across European regulatory frameworks established by the European Medicines Agency (EMA).
Neutral
InvestorPlace
7 months ago
7 Penny Biotech Stocks to Triple Your Investment
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
Neutral
GlobeNewsWire
8 months ago
Genenta Welcomes New Directors John L. Cantello, Lauren H.
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
Neutral
GlobeNewsWire
11 months ago
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial
Charts implemented using Lightweight Charts™